BioNTech’s Bold Strides: From Pandemic Savant to Cancer Trailblazer Amidst Financial Turbulence
BioNTech is transitioning from COVID-19 vaccine success to developing pioneering cancer therapies using mRNA technology. The company faces financial challenges, reporting a €700 million net loss in 2024, yet has…